GGHC
IMUX icon

Gilder Gagnon Howe & Co’s Immunic IMUX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-82
Closed -$692K – 269
2015
Q2 		$692K Sell
82
-3
-4% -$28.6K 0.01% 223
2015
Q1 		$849K Buy
+85
New +$781K 0.01% 208

Other funds holding IMUX

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gilder Gagnon Howe & Co's IMUX Position: Q3 2015 in Review

Gilder Gagnon Howe & Co sold out of Immunic (IMUX) in Q3 2015, closing a stake of 82 shares — an estimated $692K sold.

Gilder Gagnon Howe & Co first reported a position in IMUX in Q1 2015 and held it in 2 quarters. The position peaked at $849K in Q1 2015. 56 funds tracked by Wall St. Rank hold IMUX as of Q3 2015.

  • Gilder Gagnon Howe & Co reported no remaining Immunic position as of Q3 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 82 Immunic shares in Q3 2015, an estimated $692K.
  • Gilder Gagnon Howe & Co first reported a position in Immunic in Q1 2015 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Immunic position peaked at $849K in Q1 2015.
  • 56 funds tracked by Wall St. Rank held Immunic as of Q3 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2015, filed 9 Nov 2015.